Amylyx Pharmaceuticals stock
AMLXNASDAQAmylyx Pharmaceuticals, Inc., HealthcareISIN US03237H1014
43Score 43 out of 100, Weak
Price and trend
87 / 100
Price history
+142% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 44% above it.
Since November 2024 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 25% below its 52-week high. Largest decline in 5 years: 96% (January 2023 to June 2024).
Chart figures for advanced users
- SMA 50$29.72
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$20.72
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.38
- The lowest closing price of the last twelve months.
- Resistance$39.66
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Amylyx Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.84B, is number 86 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 43 out of 100 (Weak): rank 494 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $316.98M, financial debt $5.96M.Stability 69
Weaknesses
- DilutionShare count up 67% since 2020.Capital allocation 18
- Loss-makingLoss of $144.74M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 87% a year over the last 12 months.Stability 69
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2022 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. From 2022 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 2 Mar 2027in 110 days
- Last reported
- 5 Nov 2026EPS reported −$0.38 (expected −$0.38)in line with expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 3.9% since 15 Oct 2026.
- Earnings per share
- −$1.50+0.7%
- Revenue
- $80.63K0.0%
- Earnings per share
- −$1.13+3.9%
- Revenue
- $56.55M+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $51,338 in total. 6 insiders sold, $11.49M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Frates James MSale
10 Nov 2026, Chief Financial Officer
- Shares
- 20,000
- Price
- $30.55
- Value
- $611,090
- Frates James MSale
9 Nov 2026, Chief Financial Officer
- Shares
- 20,000
- Price
- $29.83
- Value
- $596,652
- Klee Justin B.Sale
9 Nov 2026, Co-Chief Executive Officer
- Shares
- 100,000
- Price
- $29.84
- Value
- $2.98M
Show 10 more
- Cohen Joshua BSale
9 Nov 2026, Co-Chief Executive Officer
- Shares
- 100,000
- Price
- $29.84
- Value
- $2.98M
- Milne George M JrSale
5 Oct 2026, Board
- Shares
- 30,000
- Price
- $27.70
- Value
- $830,904
- Bedrosian Camille LSale
10 Sept 2026, Chief Medical Officer
- Shares
- 10,028
- Price
- $32.40
- Value
- $324,868
- Frates James MSale
10 Sept 2026, Chief Financial Officer
- Shares
- 10,810
- Price
- $32.36
- Value
- $349,821
- Mazzariello GinaSale
10 Sept 2026, Chief Legal Officer
- Shares
- 9,536
- Price
- $32.46
- Value
- $309,506
- Klee Justin B.Sale
10 Sept 2026, Co-Chief Executive Officer
- Shares
- 30,464
- Price
- $32.18
- Value
- $980,263
- Cohen Joshua BSale
10 Sept 2026, Co-Chief Executive Officer
- Shares
- 30,464
- Price
- $32.19
- Value
- $980,504
- Mazzariello GinaSale
10 Jul 2026, Chief Legal Officer
- Shares
- 15,000
- Price
- $17.61
- Value
- $264,122
- Mazzariello GinaSale
9 Jul 2026, Chief Legal Officer
- Shares
- 15,000
- Price
- $18.32
- Value
- $274,746
- Firestone KarenPurchase
21 May 2026, Board
- Shares
- 3,800
- Price
- $13.51
- Value
- $51,338
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Amylyx Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- CamurusCAMX.ST $4.42B74
- Relay TherapeuticsRLAY $4.36B46
- Tango TherapeuticsTNGX $4.34B45
- Xenon PharmaceuticalsXENE $4.14B37
- AbCellera BiologicsABCL $3.9B38
- Tarsus PharmaceuticalsTARS $3.78B43
- Enliven TherapeuticsELVN $3.77B45
- Iovance BiotherapeuticsIOVA $3.74B43
ETFs that hold Amylyx Pharmaceuticals
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.23% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.11% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2024)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.